The abstract is read at the publisher; the summary is JClub's.
Extended follow-up in patients with small-cell lung cancer shows tarlatamab improves median overall survival to 13.6 months versus 8.4 with chemotherapy.
- Why it matters: Earlier results at under 12 months left uncertainty about whether survival, disease control, and tolerability persist over time after platinum-based chemotherapy.
- What they did: In DeLLphi-304, a phase III open-label randomized trial, patients received tarlatamab or chemotherapy (topotecan, lurbinectedin, or amrubicin) until progression or unacceptable toxicity, with outcomes assessed at a 18 February 2026 data cut-off.
- The result: Kaplan-Meier estimates were 55.9% and 30.3% for 12- and 24-month OS with tarlatamab versus 39% and 14.9% with chemotherapy, alongside higher response (35.4% vs 20.4%) and fewer sustained disease control events (24.4% vs 4.3%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.